Skip to Content
Merck
CN

1643419

USP

Telmisartan

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4′[(1,4′-Dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl][1,1′-biphenyl]-2-carboxylic acid, BIBR 277

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C33H30N4O2
CAS Number:
144701-48-4
Molecular Weight:
514.62
NACRES:
NA.24
PubChem Substance ID:
329751227
UNSPSC Code:
41116107
MDL number:
MFCD00918125

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Telmisartan, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)

SMILES string

CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)-c4ccccc4C(O)=O)-c5nc6ccccc6n5C

InChI key

RMMXLENWKUUMAY-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

telmisartan

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Telmisartan USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Telmisartan is a non-peptide AT1 angiotensin receptor antagonist.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dominik Wincewicz et al.
Pharmacological reports : PR, 66(3), 436-441 (2014-06-07)
The potential effect of chronic treatment with telmisartan, an angiotensin type 1 receptor blocker (ARB) and partial agonist of peroxisome proliferator--activated receptor γ (PPARγ), on stress-related disorders is a matter of considerable interest. The existing data suggest that angiotensin II
Mijeong Son et al.
Clinical therapeutics, 36(8), 1147-1158 (2014-07-07)
Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and telmisartan, an angiotensin receptor blocker, are commonly prescribed in combination for the treatment of dyslipidemia accompanied by hypertension. However, the nature of the pharmacokinetic interaction between the 2 drugs is not clearly
Yi Li et al.
Biochemical pharmacology, 93(4), 461-469 (2015-01-13)
Mesenteric adipose tissue hypertrophy is unique to Crohn's disease while the molecular basis of the crosstalk between MAT and the intestinal inflammation is largely unknown. Telmisartan is an angiotensin II type 1 receptor blocker and a peroxisome proliferator-activated receptor-receptor-γ agonist
Muralikrishna Gangadharan Komala et al.
PloS one, 9(11), e108994-e108994 (2014-11-05)
Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. Drugs inhibiting this transporter have recently been approved for clinical use and have been suggested to have
Pradip N Gore et al.
Endocrine, metabolic & immune disorders drug targets, 15(1), 64-70 (2014-12-03)
The present study was planned to focus on comparative effects of telmisartan vs lisinopril on blood pressure in patients of metabolic syndrome The study was carried out on 62 patients of metabolic syndrome from Dec 2010 to Oct 2012 in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service